Further, the majority of the patients are not only physically disabled but also even had to face mental, social, and financial losses, eventually precipitating social stigma and poverty. [1] Acknowledging the public health concern associated with the disease, distribution across different geographical regions, and the associated impairment in the quality of life/disability, the World Health Organization has initiated the global program to eliminate lymphatic filariasis in 2000. [1] [2] [3] The international stakeholders have realized this initiative as one of the fastest growing disease elimination programs in the world, and subsequent to the considerable gains achieved (viz. 5.5 billion people received preventive chemotherapy), it was decided to target elimination of the disease by the year 2020. [1, 3] The proposed target of elimination is based on two strategies, namely preventive chemotherapy (large scale administration of a single dose of two drugs [albendazole + ivermectin/diethylcarbamazine] annually for 4-6 successive years in regions where infection is prevalent to interrupt the transmission), and appropriate treatment of morbidities and prevention of disabilities. [2, 3] Variable morbidities can be managed by either surgical intervention for hydrocele or treatment of lymphedema, promotion of general cleanliness/skin care/limb elevation, and management of adenolymphangitis. [2] [3] [4] In addition, measures to ensure control of the mosquito vector, and adoption of Filariasis Test Strip newer diagnostic test to ascertain when to stop preventive chemotherapy will also play a defining role in accomplishing the target of elimination of the disease. [1, 5] Furthermore, as migration plays a significant role in the emergence and re-introduction of lymphatic filariasis, some of the nations have adopted the strategy to administer two doses of diethylcarbamazine with an interval of 6 months to prevent imported cases. [2, 3] However, a wide range of challenges like almost 55 nations yet to initiate preventive chemotherapy, the lack of coverage of the entire at-risk population in high-risk areas, shortcomings in the health system, issues with compliance to treatment, contraindications to drugs, and funding constraints have been identified in the global mission of filariasis elimination. [1] [2] [3] To conclude, the target to globally eliminate lymphatic filariasis by 2020 can be accomplished, provide all the member states and stakeholders work in collaboration to strengthen the prevention and control activities.
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